LL-37 is an antimicrobial peptide with a sequence of 37 amino acids; another name is the cathelicidin antimicrobial peptide (CAMP). [i] It’s an antimicrobial peptide (AMP), a molecule class that studies suggest may fight bacteria.
Cathelicidin, a bigger protein naturally produced, is the source of this peptide’s C-terminal. Neutrophils, keratinocytes, myelocytes, natural killer cells, and other cell types in the bone marrow all express it.
LL-37 Peptide: Mechanism of Action
Studies suggest that because of its alleged ability to modulate the immune system, LL-37 may inhibit the actions of pathogenic bacteria.
LL-37 was synthetically developed to go after the hard-to-treat germs which have developed resistance to traditional antibiotics. Antimicrobial resistance is the intended target of this unique peptide.
Most LL-37 is produced by neutrophils, the immune system’s first-line cells that engage infections. When exposed to active toll-like receptors, neutrophils secrete inactive LL-37 precursors. [ii]
Research suggests that by its membership in the class of cationic antimicrobial peptides, LL-37 may have a net positive charge of 6, allowing it to attach to and damage the negatively charged outer membrane of bacteria. [iii]
Findings suggest the immune system may be considerably strengthened due to LL-37’s potential to bring cytokines, chemokines, T cells, monocytes, and mast cells to the site of infection. [iv]
Research results suggest LL-37 may efficiently degrade the lipoprotein membranes of bacteria inside phagosomes. Biofilms are dense populations of infectious microbes, and this activity might hinder their production. The biofilm caused by Pseudomonas aeruginosa is a typical example. [v]
Researchers speculate LL-37 may promote the development of functional dendritic cells capable of antigen presentation. In addition to this, LL-37 may cause apoptosis in bacteria, killing bacteria instantly. [vi]
In addition to its potential role as an immunomodulator, scientists hypothesize LL-37 may also shield against inflammatory damage by stimulating the production of anti-inflammatory cytokines.
Studies suggest the pro-inflammatory transcription factor NF-kB may have its nuclear import inhibited by LL-37. Additionally, LL-37 may significantly decrease pro-inflammatory cytokines and chemokines in mouse research. [vii]
Research suggests one of LL-37’s lesser-examined potential action may be developing new blood vessels. It may facilitate faster wound healing by promoting both angiogenesis and the proliferation and migration of endothelial cells, which are necessary for regeneration. [viii]
LL-37 has been suggested to protect against atherosclerosis and other cardiac issues by halting the development of plaque inside the coronary arteries [ix]. Research also suggests that LL-37 may stimulate bone growth by attracting stem cells to the damaged site. [x]
LL-37 Peptide Properties
Now that we understand how LL-37 works, drawing connections to its properties is a breeze.
When triggering an inflammatory response against antibiotic-resistant bacteria, studies suggest LL-37 may be a potent antimicrobial peptide. Staphylococcus aureus stands out because it is gram-positive and resistant to several antibiotics.
Research suggests LL-37 may potentially help to overcome recurring infections by modulating the immune system via pathways that boost innate and adaptive immunity.
Regarding inflammatory autoimmune disorders, including inflammatory bowel disease, psoriasis, and arthritis, findings suggest LL-37’s anti-inflammatory properties may be invaluable. [xi]
This scenario also applies to many lung illnesses, many of which are made worse by inflammatory reactions. Therefore, researchers speculate LL-37 may slow the worsening of lung damage by reducing inflammation and protecting against infections.
Scientists hypothesize LL-37 may be a crucial anti-cancer peptide due to its alleged apoptotic properties. The development of oral squamous cell carcinoma and colon cancer cells appeared inhibited in experiments when LL-37 was presented. [xii]
It has also been suggested in studies to potentially prevent prostate cancer cells from spreading and invading other tissues. [xiii]
Additionally, studies suggest that accelerating wound healing and bone regeneration after an injury may be possible with the help of LL-37 due to its proposed potential to stimulate angiogenesis and the multiplication of mesenchymal stem cells.
Findings also imply the risk of myocardial infarctions may be greatly reduced due of LL-37’s potential role as a cardio-protective peptide, particularly within the context of atherosclerosis.
LL-37 vs TB4 (Thymosin Beta-4)
Studies suggest similar effects on injured tissues in response to the naturally occurring Thymosin beta-4 and LL-37 peptides. Researchers speculate these peptides may hasten recovery from tissue damage by encouraging new cell growth and blood vessel formation.
Research suggests that unlike Thymosin beta-4, which is secreted by the thymus, the antimicrobial peptide LL-37 is produced by neutrophils in response to microbial interaction.
LL-37 vs. Thymosin Alpha-1
These peptides have both been scientifically examined, with comparable findings under laboratory conditions. Scientists hypothesize Thymosin alpha-1 may defend against pathogens in the same way as LL-37 does.
If you are a researcher interested in purchasing peptides for research studies, visit Core Peptides for high-quality research compounds.
